PURPOSE:This randomized controlled trial was designed to compare the efficacy and safety of esketamine versus remifentanil respectively combined with propofol for painless fiberoptic bronchoscopy (FFB). METHODS:A total of 206 patients undergoing elective painless FFB were randomly divided into 2 groups. The experimental group (n = 104) received anesthesia induction with esketamine 0.5 mg/kg, propofol 2 to 3 mg/kg, and rocuronium 0.3 mg/kg, followed by maintenance with esketamine 0.5 to 3 mg·kg-1·h-1 and propofol 4 to 9 mg·kg-1·h-1. The control group (n = 102) received induction with remifentanil 1 µg/kg, propofol 2 to 3 mg/kg, and rocuronium 0.3 mg/kg, with maintenance using remifentanil 3 to 9 µg·kg-1·h-1 and propofol 4 to 9 mg·kg-1·h-1. Primary outcomes included bronchospasm incidence and airway-related indicators. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), peripheral oxygen saturation (SpO2) were recorded at 5 time points: pre-induction (T1), post-induction (T2), bronchoscope insertion (T3), 10 minutes after insertion (T4), and end of procedure (T5). Airway pressure was recorded at T3, T4, and T5. FINDINGS:Compared with the control group, the experimental group had a significantly higher incidence of bronchospasm (47.12% vs. 29.41%, P = 0.003), and a significantly higher proportion of patients with grade 2 airway secretions (76.92% vs. 33.33%), higher propofol dosage (300.01 ± 151.81 mg vs. 142.62 ± 66.72 mg), elevated SBP/DBP/HR at T3-T5, increased airway pressure at T4-T5, higher incidences of hypertension, lower incidences of hypotension and bradycardia, reduced grade 0 cough scores, increased grade 5 cough scores, decreased grade 0 to 1 sputum volume, increased grade 4 sputum volume, and prolonged recovery time (all P < 0.05). No significant differences were observed in airway stenosis grade, bronchial mucosal swelling/congestion, other adverse events, NRS pain score, operator/anesthesiologist satisfaction, operation duration, or discharge time (all P > 0.05). IMPLICATIONS:In this study of adult patients undergoing elective painless flexible fiberoptic bronchoscopy, esketamine was associated with better hemodynamic stability but increased risks of airway adverse events and prolonged recovery time, requiring vigilant perioperative management in appropriately selected patients.

Background Flexible bronchoscopy frequently provokes airway reflexes that impair patient comfort and procedural quality. Remimazolam provides effective sedation but often requires adjunctive opioids to suppress coughing and movement. Oliceridine is a G-protein-biased μ-opioid receptor agonist that may provide effective pain relief while minimising respiratory and haemodynamic side effects. However, the optimal dose of oliceridine combined with remimazolam for bronchoscopy remains unknown.Methods and analysis This is a prospective, single-centre, sex-stratified, up-and-down sequential allocation trial. Adult patients (18–65 years, American Society of Anesthesiologists I–III) undergoing painless flexible bronchoscopy will receive intravenous oliceridine followed by remimazolam (0.3 mg/kg). The initial oliceridine dose is 40 µg/kg and is adjusted in 10 µg/kg steps according to the Dixon method based on bronchoscopic response. The primary outcome is the ED50 and ED95 of oliceridine for suppressing bronchoscopic responses during remimazolam sedation in male and female patients. ED50 and ED95 values with 95% CIs will be estimated using probit regression. Secondary outcomes include respiratory and haemodynamic events, rescue medication use, recovery characteristics and satisfaction scores.Ethics and dissemination Approval for the study has been granted by the Ethics Committee of Guiyang First People’s Hospital. Written informed consent will be obtained from each participant. The findings will be shared through peer-reviewed journals and academic conferences.Trial registration ChiCTR2500114090.

ObjectiveAlthough remimazolam tosilate (RT) has demonstrated efficacy in elderly gastroscopy, its optimum dose for gastroscopy in elderly patients of varying ages is still unclear. The study aimed to determine the median effective dose (ED50) and 95% effective dose (ED95) of RT to inhibit the gastroscopy reaction in patients aged 65–74 years and 75–89 years.MethodsSixty-one elderly patients were randomized into two groups: Group A (65–74 years, n = 31) and Group B (75–89 years, n = 30). Three minutes after the recruited subjects received 0.1 μg/kg of sufentanil, RT was administered intravenously at an initial dose of 0.15 mg/kg with 0.01 mg/kg step size according to the modified Dixon’s up-and-down method (UDM). This continued until nine crossover midpoints “positive–negative” were observed.ResultsThe ED50 of RT calculated by the modified UDM for inhibiting the gastroscopy reaction in Group A (0.175 (95% confidence interval, CI, 0.166–0.183) mg/kg) was higher than that in Group B (0.163 (95% CI, 0.156–0.169) mg/kg) (p = 0.03). The ED95 estimated by probit regression analysis was 0.199 (95% CI, 0.186–0.244) mg/kg in Group A and 0.188 (95% CI, 0.175–0.232) mg/kg in Group B.ConclusionRT is a relatively safe sedative hypnotic that can provide a suitable sedative effect for elderly patients undergoing a gastroscopy.Clinical trial registrationhttp://www.chictr.org.cn, identifier ChiCTR2200062842.

HSK21542, a peripherally restricted kappa opioid receptor agonist, was evaluated for efficacy and safety in patients with postoperative pain following abdominal surgery. This was assessed in two phase 3, multicentre, randomized, double-blind, controlled trials (HSK21542-301 [ClinicalTrials.gov identifier, NCT04738357] and HSK21542-303 [ClinicalTrials.gov identifier, NCT05390905]) in China. HSK21542-301 was a dual-arm study comparing HSK21542 1.0 μg/kg with placebo, while HSK21542-303 involved three arms comparing HSK21542 1.0 μg/kg with tramadol 50 mg/dose and placebo. All treatments were administered intravenously. The primary endpoint was the time-weighted summed pain intensity differences over 24 h (SPID0-24 h). Both HSK21542-301 (least squares [LS] mean [± standard error], -39.1 [1.88] vs -27.4 [1.89]; P < 0.001) and HSK21542-303 (-64.0 [2.25] vs -45.9 [2.25]; P < 0.001) demonstrated superiority of HSK21542 over placebo in terms of SPID0-24 h, while HSK21542-303 showed non-inferiority to tramadol (LS mean difference, -1.1; 95% confidence interval, -7.4 to 5.1; P < 0.001). Furthermore, HSK21542 had a comparable safety profile to placebo, inducing fewer gastrointestinal adverse events compared with tramadol. Grade ≥3 treatment-emergent adverse events occurred in eight (5.9%) and three (2.3%) patients in the HSK21542 arm of HSK21542-301 and HSK21542-303, respectively. In conclusion, HSK21542 showed potent analgesic effect and was well tolerated in patients who underwent abdominal surgery and experienced postoperative pain.

Background:The dopamine D2/D3 antagonist amisulpride has demonstrated its superiority and efficacy in prophylaxis of postoperative nausea and vomiting (PONV). Given the branded intravenous amisulpride (Barhemsys®) has not been approved in China, there is unmet clinical need for amisulpride. Our primary objective was to ascertain the efficacy and safety of the generic intravenous amisulpride (QLG2069) in the prophylaxis of PONV. Methods:In this phase III, multicenter, randomized, double-blind, placebo-controlled study, 551 adult Chinese patients (with ≥2 Apfel risk factors for PONV) undergoing elective laparoscopic gynecological or abdominal surgery were randomly allocated in a 1:1 ratio to receive either generic intravenous amisulpride or placebo. The primary endpoint was the complete response (CR) rate, defined as the proportion of patients demonstrating neither emetic episodes (vomiting/retching) nor requiring rescue antiemetics throughout the 24-hour postoperative window. Results:Totally, 542 patients (amisulpride group: n=275; placebo group: n=267) were included in the full analysis set. Amisulpride demonstrated significantly higher CR rate compared to placebo (53.82% vs 40.07%; P=0.0011) within 24-h postoperative period. Patients treated with intravenous amisulpride exhibited significantly lower incidence of moderate-to-severe nausea (28.36% vs 37.08%; P=0.0266) and emesis (44.73% vs 57.30%; P=0.0030) compared to the incidence in the placebo group. The proportion of patients without nausea was numerically higher (45.09%) in the amisulpride group compared to that in the placebo group (37.45%), although the difference did not reach statistical significance (P=0.0685). No significant difference in the proportions of patients receiving rescue medication was noticed between the two groups (21.09% vs 28.09%; P=0.0569). The incidence of adverse events were comparable in two groups. Conclusion:The generic intravenous amisulpride was safe and effective in prophylaxis of PONV in Chinese patients with moderate-to-high risk of PONV to were undergoing laparoscopic gynecological or abdominal surgery.

Objective Ciprofol is a new sedative anesthetic drug that can be used for gastrointestinal endoscopy and induction of general anesthesia, but the appropriate dosage for use in elderly patients has not been determined. Sufentanil is a commonly used opioid in clinical practice, and this study was designed to induce anesthesia in elderly patients using sufentanil in combination with ciprofol. However, the optimal dosage of ciprofol when it is co-administered with sufentanil has not yet been established. This study was designed to find the median effective dose (ED 50 ) and 95% confidence interval (95% CI) of ciprofol for intravenous anesthesia when combined with sufentanil. Methods We studied 57 patients who were scheduled to undergo a diagnostic upper gastrointestinal endoscopy. According to age, it was divided into two groups: 65∼74 years old (group A) and over 75 years old (group B). Using the modified Dixon sequence test method, intravenous bolus of 0.1 μg/kg sufentanil was given 3 min before ciprofol is administered, the initial dose of ciprofol was 0.4 mg/kg, the upper gastrointestinal endoscopy was placed after reaching the depth of sedation, and vital signs and adverse events were recorded at each perioperative time point (T 0 -T 7 ). Results In the group A, when combined with 0.1 μg/kg sufentanil, the ED 50 of ciprofol to inhibiting responses to insertion of upper gastrointestinal endoscopy was 0.23 mg/kg, and the 95% CI was 0.09∼0.30 mg/kg; in the group B, the ED 50 was 0.18 mg/kg, and the 95% CI was 0.13∼0.22 mg/kg. Conclusion The ED 50 of ciprofol in combination with sufentanil (0.1 μg/kg) for upper gastrointestinal endoscopy in elderly patients: 0.23 mg/kg in group A and 0.18 mg/kg in group B.

Introduction Postoperative cognitive dysfunction (POCD) is a common complication following cardiac surgery, particularly in elderly patients undergoing cardiopulmonary bypass (CPB). While Sirtuin 1 (SIRT1) has been implicated in the mitigation of POCD, its potential as a predictive biomarker for POCD remains unclear. Methods Patients undergoing CPB cardiac surgery were evaluated for POCD using the Montreal Cognitive Assessment. Based on the assessment results, patients were divided into two groups, with further stratification by key factors. The correlation between these risk factors and POCD incidence was analyzed. Odds ratios were calculated for six risk factors, and the receiver operating characteristic curve analysis was used to evaluate the predictive power of early postoperative serum SIRT1 levels for POCD. Results Six risk factors—including age, education level, CPB duration, aortic occlusion duration, anesthesia duration, and early postoperative serum SIRT1—were strongly associated with POCD incidence. Patients with POCD had decreased early postoperative serum SIRT1 levels. SIRT1 was found to be a significant predictor of POCD, with high sensitivity and specificity. Additionally, neuron-specific enolase and S100β levels were elevated in POCD patients and negatively correlated with early postoperative serum SIRT1 levels. Conclusions Early postoperative serum SIRT1 serves as an effective biomarker for predicting POCD, offering both high sensitivity and specificity, and could be used to anticipate the onset of clinical POCD.

Objective: Ciprofol combined with sufentanil was used to explore median effective dose and 95% confidence interval for inhibiting the upper gastrointestinal endoscopic insertion response in elderly patients using up-and-down sequential allocation trial, provide a reference for clinical rational drug use. Methods: We studied fifty-seven patients who were scheduled to undergo a diagnostic upper gastrointestinal endoscopy. According to age, it is divided into two groups: 65~74 years old and over 75 years old. Using the modified Dixon sequence test method, intravenous bolus of 0.1 μg/kg sufentanil is given after 3 min before ciprofol is administered, the initial dose of ciprofol is 0.4 mg/kg, the upper gastrointestinal endoscopy is placed after reaching the depth of sedation. Results: In the group A, when combined with 0.1 sufentanil, the ED of ciprofol to inhibiting responses to insertion of upper gastrointestinal endoscopy was 0.23 mg/kg， and the 95% CI was 0.09~0.30 mg/kg; in the group B, the ED was 0.18mg/kg，and the 95% CI was 0.13~0.22mg/kg. Conclusion: The ED of ciprofol in combination with sufentanil (0.1 μg/kg) for upper gastrointestinal endoscopy in elderly patients: 0.23 mg/kg in group A, 0.18 mg/kg in group B.

目的 瑞马唑仑复合舒芬太尼在无痛超声内镜检查中的安全性.方法 选择 2022 年4-6月行无痛超声胃镜检查的患者 76 例,男 28 例,女 48 例,年龄 18～64 岁,BMI 18～30 kg/m2,ASAⅠ—Ⅲ级.采用随机数字表法将患者分为两组:瑞马唑仑组(R组)和丙泊酚组(P组),每组 38 例.静脉推注舒芬太尼 0.1 μg/kg,4 min后R组静脉推注瑞马唑仑 0.2 mg/kg,P组静脉推注丙泊酚 1.5 mg/kg,待患者改良警觉/镇静(MOAA/S)评分≤3 分时进行超声胃镜操作.记录检查期间、恢复期间低血压、呼吸抑制发生情况.记录镇静时间、苏醒时间、离室时间、镇静成功例数,下镜成功例数及注射痛等不良事件发生情况.记录患者、麻醉科医师、内镜医师满意度评分.结果 与P组比较,R组检查期间、恢复期间低血压发生率和呼吸抑制发生率、注射痛发生率均明显降低(P＜0.05).两组镇静时间、苏醒时间、离室时间、镇静成功率、下镜成功率、患者、麻醉科医师、内镜医师满意度评分差异均无统计学意义.结论 瑞马唑仑复合舒芬太尼在无痛超声胃镜检查围术期安全性更高,血流动力学更稳定,不良反应少,镇静效果与丙泊酚类似.

BACKGROUNDHSK3486 (ciprofol) is a 2,6-disubstituted phenol derivative that acts like propofol as an agonist at the gamma-aminobutyric acid-A (GABA(A)) receptor.OBJECTIVETo investigate the efficacy and safety of HSK3486 for general anaesthesia induction and maintenance.DESIGNA single-blinded, randomised, parallel-group, phase 3 trial.SETTINGInvolving 10 study centres, from November 24, 2020 to January 25, 2021.PATIENTSA total of 129 patients undergoing nonemergency, noncardiothoracic, and nonneurosurgical elective surgery.INTERVENTIONPatients were randomly assigned at a 2:1 ratio into HSK3486 or propofol groups, to receive HSK3486 (0.4 mg kg(-1)) or propofol (2.0 mg kg(-1)) for induction before a maintenance infusion at initial rates of 0.8 and 5.0 mg kg(-1) h(-1), and were adjusted to maintain a bispectral index (BIS) of 40-60 until the end of surgery.MAIN OUTCOME MEASURESNoninferiority between the drugs was evaluated as the lower limit of the 95% confidence interval (CI) for the between-group difference in the success rate of anesthetic maintenance (primary outcome) >-8%. Secondary outcomes included successful anaesthetic induction, full alertness and spontaneous breathing recovery, time until leaving the postanaesthesia care unit and changes in BIS. Safety profiles were also measured.RESULTSOf 129 enrolled patients, 128 completed the trial, with 86 in the HSK3486 group and 42 in the propofol group. The success rate for the maintenance of general anaesthesia was 100% for both groups, and noninferiority of HSK3486 was confirmed (95% CI -4.28% to 8.38%). No significant differences were found between the two groups of patients with regard to secondary outcomes (all P > 0.05). There appeared to be a comparable incidence of treatment for emergency adverse events (TEAEs) (80.2% vs. 81.0%, P = 1.000) and drug-related TEAEs (57.0% vs. 64.3%, P = 0.451) in the HSK3486 and propofol groups.CONCLUSIONHSK3486 had a noninferior efficacy profile compared to propofol, exhibiting excellent tolerance.

Background Remimazolam tosilate (RT) is a new type of γ-aminobutyric acid subtype A (GABAA) receptor agonist, having the possibility to be an ideal sedative drug for procedural sedation. At present, there are few studies on the effect of RT on respiratory depression in elderly patients. We aimed to evaluate the effect of RT on respiratory depression in elderly patients undergoing gastroscopy. Methods This prospective, randomized, single-blinded trial recruited patients from eight centers in China between May 2022 and July 2022. A total of 346 elderly patients undergoing gastroscopy were randomly divided into RT group (0.2 mg/kg) or propofol group (1.5 mg/kg), respectively. The primary outcome was the incidence of respiratory depression. Secondary outcomes include the incidence of sedative-related adverse events, the success rate of sedation, time to fully alert, time to loss of consciousness (LOC), time to ready for discharge, as well as the the patients, endoscopists and anethetists’ satisfaction. Results The incidence of respiratory depression was significantly reduced in the RT group compared with the propofol group (9.8% vs 17.9%, P=0.042). The time of LOC and fully alert in the RT group were longer than that in the propofol group (P < 0.05). The incidences of hypotention (50.9% vs 32.4%, P=0.001) and hypotension requiring treatment (5.8% vs 1.7%, P=0.031) were significantly higher in the propofol group than that in the RT group. The incidence and severity of injection pain were more frequently recorded in the propofol group than that in the RT group (40.5% vs 12.1%, P<0.05). There were no statistically significant differences between the two groups in terms of sedation success rates, time to ready for discharge, endoscopists and anethetists’ satisfaction and other sedative-related adverse events. Conclusion RT may be a suitable alternative sedative agent for elderly patients undergoing gastroscopy due to its safety profile.

目的:探讨基于"雨课堂"的翻转课堂联合PBL教学模式在临床麻醉实习带教中的应用效果.方法:2019年1月—2020年1月,选择贵州医科大学2015级麻醉学专业学生为研究对象,采用随机抽样的方法,将90名学生随机分为对照组和实验组.对照组采用PBL教学法,实验组采用"雨课堂"的翻转课堂结合PBL教学法.比较两组学生实习结束后的理论考核成绩和实践技能考核成绩,调查实验组学生对该联合教学法教学评价的情况.结果:实验组理论成绩和实践技能考核成绩均高于对照组,差异有统计学意义(P<0.05).95.56％学生认为基于"雨课堂"的翻转课堂联合PBL法有利于提高学习效率;97.79％学生认为有利于提高学习兴趣;93.33％学生认为有利于提高思维能力;93.33％学生认为教师教学设计合理;91.11％学生认为时间安排合理;绝大多数学生认为"雨课堂"有利于增强学习积极性,且学习方便.结论:基于"雨课堂"的翻转课堂联合PBL教学法能有效提高临床麻醉实习生的学习积极性及成绩,提升教学效果和质量.

Abstract Background To observe the therapeutic effect of conventional decompressive craniectomy with hematoma evacuation and frame-based stereotactic minimally invasive surgery (MIS) for supratentorial intracranial hematoma with herniation. Methods One hundred forty-nine patients with hypertensive ICH complicated with tentorial herniation were reviewed and analyzed in the present study. The intracranial hematoma was evacuated by emergency surgery within 6 h after admission. According to the authorized representatives’ wishes and consent, 74 of the 149 patients were treated by conventional decompressive craniectomy followed by hematoma removal, defined as the CDC group, and the remaining 75 patients underwent frame-based stereotactic MIS for ICH evacuation, defined as the MIS group. The intervals between the admission to surgery, the duration of surgery, the amount of iatrogenic bleeding, the occurrence of postoperative rebleeding, and the recovery of neurological functions were compared between the two groups. All patients were followed up for 3 months. Secondary epilepsy, survival in a vegetative state, severe pulmonary complications, mortality, and activities of daily living (ADL) classification were also recorded and compared. Results The interval between admission and surgery, the duration of surgery, and intraoperative blood loss in the MIS group were significantly decreased compared to the CDC group. The mortality rate, the rate of rebleeding, prevalence of vegetative state, and severe pulmonary complications in the MIS group were remarkably decreased compared to the CDC group. In the MIS group, the survivors’ (ADL) grade also showed advantages. Conclusions In the surgical treatment of hypertensive ICH complicated with tentorial herniation, frame-based stereotactic MIS for ICH showed advantages compared to conventional open surgery.

患者,男,31岁,165 cm,40 kg,因"发现气管食管瘘10 d余"入院.患者2个月余前高处坠落伤导致"特重型颅脑损伤",行"颅内血肿清除术",术后1周行"气管切开术",1个月前气管切开处封管后拨管,10 d前呼吸困难逐渐加重,行纤维支气管镜检查见气管上段有一约3 cm × 3 cm瘘口.既往体健.查体:意识障碍不能对答,心律齐, HR 130次/分,双肺呼吸音粗,可闻及散在湿啰音.辅助检查:WBC 11. 26 × 109/L,中性粒细胞百分比77. 2％,Hb 100 g/L,总蛋白60. 13 g/L,白蛋白34. 4 g/L,白细胞介素-6( IL-6) 24. 4 pg/ml,C反应蛋白(CRP) 19. 5 mg/L.血气分析(FiO250％):pH 7. 43, PaCO231 mmHg,PaO2116 mmHg.诊断:(1)气管食管瘘;(2)重症肺炎;(3)颅脑损伤开颅术后;(4)气管切开术后.拟行"气道支架置入术".

Objectives: Clinically, there is no effective therapy for postoperative cognitive dysfunction (POCD). Inflammation after surgery is closely associated with POCD. Methods: In this study, we explored the role of sirtuin 1 (SIRT1) in POCD. POCD in mice was induced by cardiac surgery. The mRNA and protein levels of related genes were determined by real-time polymerase chain reaction and western blot, respectively. Plasma concentrations of inflammatory factors were measured using an ELISA kit. Novel object and novel location recognition tests were carried out to measure recognition ability. The Morris water maze (MWM) test was performed to measure learning and memory ability. Results: There was a clear decrease in SIRT1 expression after POCD. The SIRT1 activator SRT1720 promoted recognition, learning, and memory ability of mice with POCD. Moreover, SRT1720 treatment greatly inhibited plasma inflammatory cytokine levels and TLR4 and P65 protein expression in the hippocampus of POCD mice. The effect of SRT1720 on POCD was in a TLR4-dependent manner. Conclusions: SIRT1 mediates the improvement of cardiac surgery-induced postoperative cognitive dysfunction via the TLR4/NF-kappa B pathway.

目的 评价超声引导下髂筋膜间隙阻滞(FICB)在小儿发育性髋脱位(DDH)术中的应用效果.方法 选取年龄1～7岁、美国麻醉医师协会(ASA)Ⅰ～Ⅱ级,择期行单侧DDH手术的患儿40例,随机分为两组:超声引导髂筋膜间隙阻滞组(F组)和对照组(C组),每组20例.全麻诱导后行超声引导下髂筋膜间隙阻滞:F组给予0.2％罗哌卡因1 mL/kg,C组给予生理盐水1 mL/kg,总量均不超过30 mL.记录切皮前(T1)、切皮时(T2)、切皮后5 min(T3)、股骨粗隆下截骨时(T4)、术毕(T5)的心率(HR)、平均动脉压(MAP);术中及恢复室芬太尼用量;术后1、4、24和48 h疼痛行为学评分(FLACC);术后24 h患儿父母的满意度及不良反应发生情况.结果 T2、T3、T4及T5时刻点F组HR、MAP均比C组低;F组术中及恢复室芬太尼用量较C组显著减少;F组术后1h、4h和24 h疼痛行为学评分较C组显著降低,F组患儿家属满意度显著提高,不良反应较C组少.结论 超声引导下FICB用于小儿DDH手术镇痛完善,血流动力学稳定,不良反应少.

Vincristine is a toxic chemotherapeutic agent which often triggers neuropathic pain through inflammation. Morin isolated from figs (Ficus carica) exerts anti-inflammatory and neuroprotective activities. We investigated whether morin ameliorates vincristine-induced neuropathic pain and the underlying mechanism. Vincristine was injected i.p. for 10 days (day 1–5 and day 8–12). Morin was orally administered every other day from day 1 to 21. The pain behaviors were determined by measuring paw withdrawal threshold (PWT) and paw withdrawal latency (PWL). The axons of sciatic nerves were stained with toluidine blue to study the histological abnormality. Function deficit of sciatic nerves was evaluated by sciatic functional index and the sciatic nerve conduction velocity. Neuronal excitability was assessed electrophysiologically and inflammatory mediators were detected using western blotting in dorsal root ganglia. The vincristine-induced reduction in PWT, PWL, and body weight gain was attenuated by morin. Morin restored the sciatic nerve deficits both histologically and functionally in vincristine-injected rats. The vincristine-induced neuronal hyperexcitability and increase in the expression of IL-6, NF-κB, and pNF-κB were abolished after morin administration. This study suggests that morin treatment suppressed vincristine-induced neuropathic pain by protecting the sciatic nerve and inhibiting inflammation through NF-κB pathway.

目的 探索适合麻醉科专业住院医师规范化培训术前访视的新方法,以保障和提高培训质量.方法 通过使用有丰富临床实践经验和教学经验的老师模拟手术患者,情景再现住院医师了解病史、评估患者对麻醉手术耐受能力、交代相关风险、签署知情同意书等术前访视的重要环节,并就麻醉方案、风险与患者进行充分的交流,制订相应的麻醉计划.作为标准化患者的老师对参与查房的住院医师表现有了全面地了解,总结查房病例的特点,针对性的对存在的问题和不足做出指导.结果临床教师不需要长时间培训即可作为标准化患者投入教学查房,与传统讲授模式相比,住院医师能在教师标准化患者的情景模拟中获得更接近临床的指导.结论 教师标准化患者可在麻醉科专业住院医师规范化培训教学查房中推广应用.

目的 比较UE可视喉镜和直接喉镜用于喉部新生物病人气管插管的并发症发生率,声门暴露情况,插管成功率.方法 120例ASAⅠ～Ⅱ级择期行支撑喉镜手术的喉部新生物病人被随机分为UE可视喉镜组(U组n=60)和直接喉镜组(M组n=60),全麻诱导完成后进行气管插管.观察两组插管并发症、Cormark-Lehane分级、插管时间、插管成功率.结果 插管并发症发生率、声门暴露分级、插管时间U组低于M组(P<0.05).结论:UE可视喉镜喉镜用于喉部新生物病人气管插管声门暴露良好,插管并发症少,用时少的优点.